{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:25Z","timestamp":1790666545630,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Severe neutropenia (SN) and febrile neutropenia (FN) are clinically significant safety concerns of sacituzumab govitecan-hziy (SG). We sought to compare the rates of SN and FN from clinical trials to real-world experience, correlate factors with SN and FN, and quantify granulocyte colony-stimulating factor (G-CSF) use in HER2-negative (HER2-) metastatic breast cancer (mBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of patients treated with SG for advanced HER2- BC at a single US institution with a diverse patient population. The rates of SN and FN, stratified by receptor status, were compared to their respective phase III clinical trials. Multivariable logistic regression was used to evaluate factors associated with SN and FN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 87 patients treated with SG, 10 patients received primary prophylaxis. Of the 77 patients who didn\u2019t receive primary G-CSF prophylaxis, 49% and 3.9% patients developed SN and FN, respectively. SN and FN rates did not differ in the HR\u2009+\u2009\/HER- mBC or mTNBC subgroups compared to clinical trials. Factors evaluated in this study were not shown to be associated with SN. Overall, 44% (38\/87) required a dose interruption or reduction due to SN or FN. 11% (10\/87) and 60% (52\/87) received G-CSF as primary and secondary prophylaxis respectively, with a total G-CSF drug cost of $2.1 million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SG-induced SN and FN rates were similar to those reported in clinical trials, both in the HR\u2009+\u2009\/HER- mBC and mTNBC groups. Due to small sample size, we did not identify any statistically significant risk factors of SG-associated SN. Our study provided insights into G-CSF use patterns and costs in real-world SG therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07971-z","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:04:14Z","timestamp":1776391454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis"],"prefix":"10.1007","volume":"217","author":[{"given":"Grace","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincong Q.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"7971_CR1","unstructured":"Trodelvy [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2025 Mar. Available from: https:\/\/www.trodelvyhcp.com\/"},{"issue":"16","key":"7971_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"10411","key":"7971_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10411):1423\u20131433","journal-title":"Lancet"},{"key":"7971_CR4","unstructured":"National Comprehensive Cancer Network. Hematopoietic Growth Factors. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Version 1.2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf"},{"key":"7971_CR5","doi-asserted-by":"crossref","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al (2015) American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.;33(28):3199\u2013212.","DOI":"10.1200\/JCO.2015.62.3488"},{"issue":"1","key":"7971_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D et al (2022) Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. npj Breast Cancer 8(1):98","journal-title":"npj Breast Cancer"},{"issue":"9","key":"7971_CR7","first-page":"2787","volume":"25","author":"AA Kawatkar","year":"2017","unstructured":"Kawatkar AA, Farias AJ, Chao C et al (2017) Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer 25(9):2787\u20132795","journal-title":"Support Care Cancer"},{"issue":"3","key":"7971_CR8","first-page":"615","volume":"23","author":"R Pathak","year":"2015","unstructured":"Pathak R, Giri S, Aryal MR et al (2015) Mortality, length of stay, and health care costs of febrile neutropenia\u2013related hospitalizations among patients with breast cancer in the United States. Support Care Cancer 23(3):615\u2013617","journal-title":"Support Care Cancer"},{"key":"7971_CR9","unstructured":"U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers: Hospital services in U.S. city average. Series ID: CUUR0000SEMD01. https:\/\/data.bls.gov\/data\/. Accessed March 30, 2026."},{"issue":"Suppl 16","key":"7971_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2024.42.16_suppl.1572","volume":"42","author":"S Priyadarshini","year":"2024","unstructured":"Priyadarshini S, Petucci J, Katoch A et al (2024) Real world study of racial disparities associated with toxicities of sacituzumab govitecan. J Clin Oncol 42(Suppl 16):1572","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"7971_CR11","volume":"43","author":"M Oye","year":"2025","unstructured":"Oye M, Tarekegn K, Ji X, Liu Y et al (2025) Clinical outcomes of black versus non-Hispanic white women with stage IV breast cancer treated with sacituzumab at Emory. J Clin Oncol 43(Suppl 16):e13141","journal-title":"J Clin Oncol"},{"key":"7971_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","volume":"88","author":"C Ray-Coquard","year":"2003","unstructured":"Ray-Coquard C, Borg T, Bachelot C et al (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88:181\u2013186","journal-title":"Br J Cancer"},{"key":"7971_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.leukres.2012.02.002","volume":"36","author":"A Salar","year":"2012","unstructured":"Salar A, Haioun C, Rossi FG et al (2012) The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 36:548\u2013553","journal-title":"Leuk Res"},{"key":"7971_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00280-007-0648-8","volume":"62","author":"H Ozawa","year":"2008","unstructured":"Ozawa H, Minami H, Sato H (2008) Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol 62:551\u2013557","journal-title":"Cancer Chemother Pharmacol"},{"key":"7971_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/annonc\/mdl321","volume":"18","author":"E Alexandre","year":"2007","unstructured":"Alexandre E, Rey V, Girre S et al (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 18:168\u2013172","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07971-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:29:57Z","timestamp":1784017797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07971-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7971"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07971-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"22"}}